National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Egypt has the highest prevalence of HCV specially genotype 4. Both host and viral factors are important predictors of the efficacy of PEG-IFN/RBV therapy. The aim of this study was to investigate the mutational diversity of HCV core and NS5A regions and variation ofIL28B gene to predict virological response. Thirty HCV patients were included in this study. Detection of viral load, amplification and direct sequencing of the core and NS5A genes, determination of IL28B SNPs rs12979860 and rs8099917 polymorphisms were done. Equal percentage 3.3% of patients were carrying core mutations at position 70, and 91, while 6.7% had mutations at position 71. The mean number of aa mutations in IRRDR (8.4 ± 5.5 vs. 8.3 ± 5.8) and in ISDR (6.9 ± 6.2 vs. 4.1 ± 1.8). This difference did not reach the statistical significant difference between SVR and non-responders. Regarding IL28B polymorphism for rs12979860 CC alleles achieved SVR compared to 90.9% with CT and 50% with TT alleles; for rs8099917 66.7% of patients with either GT or GG genotype achieved SVR. IL28B rs12979860 polymorphism, severity of fibrosis, and NS5A ISDR ≥2 are useful markers for predicting the outcome of PEG-IFN/RBV therapy.
Citations |
 |
 |
 |
 |
